Methylation Biosignature in Childhood Chronic Kidney Disease (childhoodCKD)

Chang Gung Medical Foundation

Status: Completed

Conditions: Chronic Kidney Disease; Cardiovascular Disease

Treatments: Other: Methylation biosignature

Study type: Observational

Funder types: Other

Identifiers

NCT02022046

102-4131C

Details and patient eligibility

About

Chronic kidney disease (CKD) and end-stage renal disease are highly prevalent in Taiwan. Cardiovascular disease (CVD) is the most common cause of death in children with CKD. Nitric oxide (NO) deficiency links CKD and CVD. Asymmetric dimethylarginine (ADMA), a NO synthase inhibitor, its level is increased in kidney disease and cardiovascular disease and serves as a methylation biomarker.

In addition to ADMA, uremic environment, hyperhomocysteinemia (Hcy) and oxidative stress may affect DNA methylation. S-adenosylmethionine (SAM) is an important human methyl donor. S-adenosylhomocysteine (SAH) is demethylated product. Methylenetetrahydrofolate reductase (MTHFR), a folate metabolism enzyme can regulate methylation pathway.

The investigators intend to examine whether ADMA, SAM/SAH ratio, Hcy, and MTHFR gene methylation can serve as biosignature to predict CVD in children with CKD children.

Enrollment: 69 patients

Sex: All

Ages: 3 to 18 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• chronic kidney disease stage 1-4
• Volunteer

Exclusion criteria

• pregnancy
• renal transplant
• congenital heart disease
• not able to be adherent/complaint with study procedure
• not volunteer

Trial design

69 participants in 1 patient group

2/study, control

Description:

Study group: children aged\<18 years with chronic kidney disease Control group: children aged\<18 years without chronic kidney disease Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.

Treatment:

Other: Methylation biosignature